Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk-Reference-Cited by-同舟云学术

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

Published:2020-02-05 Issue:3 Volume:22 Page:442-451
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Husain Mansoor¹^ORCID,Bain Stephen C.²^ORCID,Jeppesen Ole K.³,Lingvay Ildiko⁴^ORCID,Sørrig Rasmus³^ORCID,Treppendahl Marianne B.³,Vilsbøll Tina⁵^ORCID

Affiliation:

1. Ted Rogers Centre for Heart ResearchToronto General Hospital Research Institute Toronto Canada

2. Swansea University Medical School, Diabetes Research Unit Cymru Swansea UK

3. Novo Nordisk A/S Søborg Denmark

4. UT Southwestern Medical Center, Internal Medicine and Population and Data Sciences Dallas Texas

5. Steno Diabetes Center CopenhagenGentofte Hospital, University of Copenhagen Copenhagen Denmark

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13955

Reference44 articles.

1. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

2. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

3. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

4. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Cited by 124 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Utilization and cost of non‐insulin glucose‐lowering drugs in Australia from 2013 to 2023;Diabetes, Obesity and Metabolism;2024-09-02

2. FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond;Journal of Hepatology;2024-09

3. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review;Cureus;2024-09-01

4. Cardiovascular and diabetes outcomes among patients with obesity and type 2 diabetes after metabolic bariatric surgery or glucagon-like peptide 1 receptor agonist treatment;British Journal of Surgery;2024-08-30

5. Oral Semaglutide in Type 2 Diabetes: Clinical–Metabolic Outcomes and Quality of Life in Real-World Practice;Journal of Clinical Medicine;2024-08-13